HRP20161504T1 - Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga - Google Patents

Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga Download PDF

Info

Publication number
HRP20161504T1
HRP20161504T1 HRP20161504TT HRP20161504T HRP20161504T1 HR P20161504 T1 HRP20161504 T1 HR P20161504T1 HR P20161504T T HRP20161504T T HR P20161504TT HR P20161504 T HRP20161504 T HR P20161504T HR P20161504 T1 HRP20161504 T1 HR P20161504T1
Authority
HR
Croatia
Prior art keywords
peptide
seq
tumors
cancer
cell
Prior art date
Application number
HRP20161504TT
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20161504T1 publication Critical patent/HRP20161504T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)

Claims (17)

1. Peptid koji se sastoji od sekvence LTFGDVVAV (SEQ ID br. 10).
2. Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid ima sposobnost vezivanja s molekulom humanog glavnog kompleksa tkivne podudarnosti (MHC) klase I, i pri čemu navedeni peptid može stimulirati CD4 ili CD8 T-stanice.
3. Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze.
4. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, pri čemu je navedeni peptid dio fuzioniranog proteina, posebice sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
5. Nukleinska kiselina, koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4.
6. Ekspresivni vektor koji može eksprimirati nukleinsku kiselinu u skladu s patentnim zahtjevom 5.
7. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u medicini.
8. Stanica domaćin koja se sastoji od nukleinske kiseline u skladu s patentnim zahtjevom 5 ili vektor ekspresije u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
9. Metoda za proizvodnju peptida u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 metoda je koja se sastoji od kultiviranja stanice domaćina u skladu s patentnim zahtjevom 8 koja eksprimira nukleinsku kiselinu u skladu s patentnim zahtjevom 5 ili vektor ekspresije u skladu s patentnim zahtjevom 6, i izoliranjem peptida iz stanice domaćina ili medija za kultiviranje.
10. In vitro metoda za proizvodnju aktiviranih citotoksičnih T- limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim od patentnih zahtjeva 1 ili 2.
11. Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 10, koji selektivno prepoznaje stanicu koja abnormalno eksprimira polipeptid koji se sastoji od sekvence aminokiselina navedene u bilo kojem od patentnih zahtjeva 1 ili 2.
12. An effective broj citotoksičnih T-limfocita (CTL) kako je definirano u patentnom zahtjevu 11 za uporabu u metodi za uništavanje ciljanih stanica kod pacijenata čije ciljane stanice abnormalno eksprimiraju polipeptid koji se sastoji od sekvence aminokiselina navedene u bilo kojem od patentnih zahtjeva 1 ili 2.
13. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u liječenju karcinoma ili za uporabu u proizvodnji cjepiva protiv karcinoma.
14. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u skladu s patentnim zahtjevom 13, pri čemu je navedeni karcinom odabran iz astrocitoma, pilocitičnog astrocitoma, disembrioplastičnog neuroepitelijalnog tumora, oligodendroglioma, ependimoma, glioblastoma multiforme, mješovitih glioma, oligoastrocitoma, meduloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, ganglioglioma, gangliocitoma, centralnog gangliocitoma, primitivnih neuroektodermalnih tumora (PNET, npr. meduloblastoma, meduloepitelioma, neuroblastoma, retinoblastoma, ependimoblastoma), tumora parenhima epifize (npr. pineocitoma, pineoblastoma), tumora ependimalnih stanica, tumora koroidnog pleksusa, neuroepitelialnih tumora nejasnog podrijetla (npr. gliomatoza mozga, astroblastom), glioblastoma, tumora prostate, karcinoma dojke, kacinoma jednjaka, kolorektalnog karcinoma, svetlostaničnog karcinoma bubrežnih stanica, karcinoma pluća, SŽS-a, jajnika, melanoma, karcinoma pankreasa, skvamocelularnog karcinoma, leukemije i meduloblastoma, kolona, rektuma, želuca, bubrega, pluća, pancreasa, prostate, kože i drugih tumora koji pokazuju pretjeranu ekspresiju proteina iz kojeg su dobiveni peptidi SEQ ID br. 10.
15. Peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4 za uporabu u skladu s patentnim zahtjevom 13 ili 14, pri čemu se navedeno cjepivo nadalje sastoji od najmanje jednog dodatnog peptida odabranog iz SEQ ID br. 1 do SEQ ID br. 9, i SEQ ID br. 11 do SEQ ID br. 26.
16. Komplet koji sadrži posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku.
17. Komplet u skladu s patentnim zahtjevom 16, nadalje sadrži najmanje još jedan peptid odabran iz grupe koja se sastoji od peptida u skladu s SEQ ID br. 1 do SEQ ID br. 9, i SEQ ID br. 11 do SEQ ID br. 26.
HRP20161504TT 2008-10-01 2016-11-15 Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga HRP20161504T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors

Publications (1)

Publication Number Publication Date
HRP20161504T1 true HRP20161504T1 (hr) 2016-12-30

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
HRP20201025TT HRP20201025T8 (hr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20150223TT HRP20150223T8 (hr) 2008-10-01 2015-02-26 Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za lijeäśenje glioblastoma (gbm-a) i drugih karcinoma
HRP20160915TT HRP20160915T1 (hr) 2008-10-01 2016-07-20 Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20161504TT HRP20161504T1 (hr) 2008-10-01 2016-11-15 Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20170115TT HRP20170115T1 (hr) 2008-10-01 2017-01-24 Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma
HRP20182151TT HRP20182151T1 (hr) 2008-10-01 2018-12-18 Inovativna imunoterapija protiv nekoliko tumora uključujući neuronske i moždane tumore
HRP20190202TT HRP20190202T1 (hr) 2008-10-01 2019-01-31 Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
HRP20200110TT HRP20200110T1 (hr) 2008-10-01 2020-01-23 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200722TT HRP20200722T1 (hr) 2008-10-01 2020-05-05 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200988TT HRP20200988T1 (hr) 2008-10-01 2020-06-19 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201015TT HRP20201015T8 (hr) 2008-10-01 2020-06-26 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201228TT HRP20201228T1 (hr) 2008-10-01 2020-08-06 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HRP20201025TT HRP20201025T8 (hr) 2008-10-01 2009-09-28 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20150223TT HRP20150223T8 (hr) 2008-10-01 2015-02-26 Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za lijeäśenje glioblastoma (gbm-a) i drugih karcinoma
HRP20160915TT HRP20160915T1 (hr) 2008-10-01 2016-07-20 Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga

Family Applications After (8)

Application Number Title Priority Date Filing Date
HRP20170115TT HRP20170115T1 (hr) 2008-10-01 2017-01-24 Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma
HRP20182151TT HRP20182151T1 (hr) 2008-10-01 2018-12-18 Inovativna imunoterapija protiv nekoliko tumora uključujući neuronske i moždane tumore
HRP20190202TT HRP20190202T1 (hr) 2008-10-01 2019-01-31 Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
HRP20200110TT HRP20200110T1 (hr) 2008-10-01 2020-01-23 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200722TT HRP20200722T1 (hr) 2008-10-01 2020-05-05 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200988TT HRP20200988T1 (hr) 2008-10-01 2020-06-19 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201015TT HRP20201015T8 (hr) 2008-10-01 2020-06-26 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201228TT HRP20201228T1 (hr) 2008-10-01 2020-08-06 Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Country Status (25)

Country Link
US (19) US8119139B2 (hr)
EP (12) EP2172211B1 (hr)
JP (10) JP5855940B2 (hr)
KR (6) KR101883426B1 (hr)
CN (3) CN106986919A (hr)
AU (2) AU2009300087B2 (hr)
BR (2) BRPI0920759A2 (hr)
CA (9) CA2936920C (hr)
CY (11) CY1116302T1 (hr)
DK (12) DK2172211T3 (hr)
EA (3) EA023378B1 (hr)
ES (12) ES2536465T3 (hr)
HK (2) HK1159526A1 (hr)
HR (12) HRP20201025T8 (hr)
HU (11) HUE031030T2 (hr)
LT (10) LT2172212T (hr)
MX (3) MX2011003539A (hr)
NZ (4) NZ603016A (hr)
PL (12) PL2172211T3 (hr)
PT (12) PT2172211E (hr)
RS (12) RS53782B1 (hr)
SI (12) SI2172211T1 (hr)
TR (2) TR201900809T4 (hr)
UA (3) UA103202C2 (hr)
WO (2) WO2010037514A2 (hr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
NZ592261A (en) * 2007-07-27 2012-09-28 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
HUE024541T2 (hu) 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011293522B2 (en) * 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
CN103547283A (zh) * 2010-12-14 2014-01-29 伊玛提克斯生物技术有限公司 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
JP2014526517A (ja) 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ 血液脳関門を通過することができるナノ抱合体
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CA2862706C (en) 2012-01-20 2021-08-03 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
PT3536334T (pt) 2012-05-16 2021-09-27 Stemline Therapeutics Inc Vacinas contra o cancro dirigidas a células estaminais cancerígenas
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI777195B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（三）
HRP20211852T1 (hr) 2013-08-05 2022-03-18 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
SI3689899T1 (sl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. MND promotor kimeričnih antigenskih receptorjev
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
JP6663359B2 (ja) 2014-06-06 2020-03-11 ブルーバード バイオ， インコーポレイテッド 改善されたｔ細胞組成物
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
WO2016070928A1 (en) * 2014-11-06 2016-05-12 Orphan Synergy Europe - Pharma Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
NZ770737A (en) 2014-12-12 2024-07-05 2Seventy Bio Inc Bcma chimeric antigen receptors
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HUE056607T2 (hu) * 2014-12-23 2022-02-28 Immatics Biotechnologies Gmbh Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN107810193B (zh) * 2015-05-06 2022-03-22 伊玛提克斯生物技术有限公司 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016200787A2 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SI3319985T1 (sl) * 2015-07-06 2021-01-29 Immatics Biotechnologies Gmbh Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku prostate in drugim oblikam raka
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI782433B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
WO2017106638A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN109620949A (zh) * 2016-03-13 2019-04-16 曹帅 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
IL261787B2 (en) 2016-03-16 2023-03-01 Immatics Biotechnologies Gmbh Nucleic acid-treated t-cells and receptor t-cells for use in immunotherapy against types of cancer
CR20180530A (es) * 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
PT3518948T (pt) * 2016-10-03 2023-07-17 Ottawa Hospital Res Inst Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
CA3042424A1 (en) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3558339B1 (en) * 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102089072B1 (ko) 2017-01-06 2020-03-17 주식회사 유틸렉스 항-인간 4-1bb 항체 및 그의 용도
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP4169528A1 (en) * 2018-04-11 2023-04-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
WO2020206385A1 (en) 2019-04-05 2020-10-08 Earli Inc. Improved methods and compositions for synthetic biomarkers
US10937541B2 (en) * 2019-05-28 2021-03-02 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
CN114072516A (zh) 2019-05-30 2022-02-18 磨石生物公司 经修饰的腺病毒
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113444149A (zh) * 2020-03-18 2021-09-28 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4203994A4 (en) * 2020-08-28 2024-07-03 Torigen Pharmaceuticals Inc PREPARATIONS WITH IMPROVED IMMUNE MEMORY AND USES THEREOF
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0879282B1 (en) 1996-01-17 2003-07-02 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
CA2262007A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
EP0910641A1 (en) * 1997-02-13 1999-04-28 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999028349A2 (en) * 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20070004655A9 (en) * 1998-04-27 2007-01-04 Murphy Gerald P Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
CA2393002A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030139327A9 (en) * 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046416A2 (en) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) * 2000-12-08 2002-06-13 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
JP2006516258A (ja) * 2002-12-27 2006-06-29 シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ ワクチンおよび抗腫瘍ワクチンを調製する方法
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
CA2554195C (en) * 2004-01-23 2011-02-22 Green Peptide Co., Ltd. Peptide originating in epidermal growth factor receptor (egfr)
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
JP5087925B2 (ja) * 2004-12-07 2012-12-05 東レ株式会社 新規癌抗原ペプチド及びその用途
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
ES2330013T3 (es) * 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
DE602005005196T2 (de) 2005-09-05 2008-06-26 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) * 2007-03-06 2008-09-12 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
SG11201609911YA (en) * 2014-05-28 2016-12-29 Nono Inc Chloride salt of tat-nr2b9c
CA3021159A1 (en) * 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
EP3679065A4 (en) * 2017-09-06 2021-05-19 California Institute of Technology SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)

Also Published As

Publication number Publication date
PT2341927T (pt) 2016-08-02
PT3132801T (pt) 2020-02-04
HRP20182151T1 (hr) 2019-02-08
HRP20200722T1 (hr) 2020-10-16
PT2172211E (pt) 2015-03-09
UA110599C2 (uk) 2016-01-25
ES2788129T8 (es) 2020-11-04
US10047124B2 (en) 2018-08-14
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
CY1121258T1 (el) 2020-05-29
HUE030296T2 (en) 2017-04-28
US8961985B2 (en) 2015-02-24
RS53782B1 (en) 2015-06-30
CA2936887C (en) 2019-11-12
EP2172211A1 (en) 2010-04-07
JP6150859B2 (ja) 2017-06-21
ES2770090T3 (es) 2020-06-30
US20100158931A1 (en) 2010-06-24
EP3120869B1 (en) 2020-07-22
US20210261614A1 (en) 2021-08-26
CA2936870A1 (en) 2010-04-08
EP3120870B1 (en) 2020-04-01
US20170326217A1 (en) 2017-11-16
LT3069728T (lt) 2019-02-11
PT2172212T (pt) 2016-12-22
JP2012504393A (ja) 2012-02-23
NZ591855A (en) 2012-11-30
PL2172212T3 (pl) 2017-04-28
HRP20201025T8 (hr) 2022-01-07
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
NZ603016A (en) 2014-05-30
HRP20170115T1 (hr) 2017-03-24
ES2788129T3 (es) 2020-10-20
KR20160103558A (ko) 2016-09-01
US20210253637A1 (en) 2021-08-19
EP3069728B1 (en) 2018-11-14
PL3120868T3 (pl) 2020-08-24
SI3120868T1 (sl) 2020-08-31
KR20220058655A (ko) 2022-05-09
LT3111952T (lt) 2018-12-27
HK1159526A1 (zh) 2012-08-03
HRP20201015T1 (hr) 2020-10-16
KR20180088494A (ko) 2018-08-03
EA023013B1 (ru) 2016-04-29
US20190010190A1 (en) 2019-01-10
WO2010037514A3 (en) 2010-06-03
CY1121098T1 (el) 2019-12-11
CY1122913T1 (el) 2021-10-29
US20160355550A1 (en) 2016-12-08
RS58443B1 (sr) 2019-04-30
EP3106175A1 (en) 2016-12-21
LT3120869T (lt) 2020-11-10
JP2017023136A (ja) 2017-02-02
US20130309193A1 (en) 2013-11-21
DK3120868T3 (da) 2020-06-22
HRP20200988T1 (hr) 2020-10-16
CN102170901B (zh) 2015-01-07
CA2936887A1 (en) 2010-04-08
JP2014239681A (ja) 2014-12-25
SI2331118T1 (sl) 2017-01-31
SI3124043T1 (sl) 2020-07-31
JP2017029135A (ja) 2017-02-09
US8318677B2 (en) 2012-11-27
EP3120870A1 (en) 2017-01-25
HRP20190202T1 (hr) 2019-03-22
JP6367266B2 (ja) 2018-08-01
CA2936920C (en) 2019-12-03
EP2331118A1 (en) 2011-06-15
US20160376313A1 (en) 2016-12-29
RS60385B1 (sr) 2020-07-31
ES2710608T3 (es) 2019-04-26
US8653035B2 (en) 2014-02-18
KR20200085381A (ko) 2020-07-14
NZ591882A (en) 2012-12-21
CY1118702T1 (el) 2017-07-12
EP2341927B1 (en) 2016-05-04
CY1123113T1 (el) 2021-10-29
SI3106175T1 (sl) 2020-08-31
EP3111952B1 (en) 2018-10-31
JP6214066B2 (ja) 2017-10-18
US20160376316A1 (en) 2016-12-29
CA2936868A1 (en) 2010-04-08
PT3120868T (pt) 2020-07-16
KR20110082155A (ko) 2011-07-18
EP3069728A1 (en) 2016-09-21
EA201401104A1 (ru) 2015-05-29
DK3132801T3 (da) 2020-02-10
CY1123098T1 (el) 2021-10-29
KR101756488B1 (ko) 2017-07-11
US20160376312A1 (en) 2016-12-29
US20160376317A1 (en) 2016-12-29
MX2011003540A (es) 2011-06-20
DK3111952T3 (en) 2019-01-28
PT2331118T (pt) 2017-02-06
CA2739387C (en) 2019-10-29
EP2172212B1 (en) 2016-10-05
PL2341927T3 (pl) 2016-11-30
CN102170900A (zh) 2011-08-31
PL3120870T3 (pl) 2020-07-27
JP6294914B2 (ja) 2018-03-14
CA2936982C (en) 2019-12-03
JP2016145210A (ja) 2016-08-12
HUE049366T2 (hu) 2020-09-28
ES2802227T3 (es) 2021-01-18
AU2009300088B2 (en) 2014-09-04
PT3120870T (pt) 2020-07-01
HUE042115T2 (hu) 2019-06-28
LT3132801T (lt) 2020-02-10
JP2012504563A (ja) 2012-02-23
CA2936924C (en) 2019-07-16
CA2936869A1 (en) 2010-04-08
DK3124043T3 (da) 2020-05-04
EP3120868A1 (en) 2017-01-25
JP2017000148A (ja) 2017-01-05
AU2009300087B2 (en) 2014-09-04
JP2017018101A (ja) 2017-01-26
JP6294913B2 (ja) 2018-03-14
BRPI0920791A2 (pt) 2019-12-10
CY1123526T1 (el) 2022-03-24
CY1123089T1 (el) 2021-10-29
KR101687840B1 (ko) 2016-12-19
EP3124043B1 (en) 2020-04-29
RS60338B1 (sr) 2020-07-31
DK2331118T3 (da) 2017-01-09
MX338294B (es) 2016-04-11
MX2011003539A (es) 2011-06-20
KR102133402B1 (ko) 2020-07-14
US8895514B2 (en) 2014-11-25
CY1122677T1 (el) 2021-03-12
RS58229B1 (sr) 2019-03-29
EP2172212A3 (en) 2010-04-14
CA2739384C (en) 2017-05-02
HUE041446T2 (hu) 2019-05-28
WO2010037514A2 (en) 2010-04-08
CA2936870C (en) 2019-11-26
ES2536465T3 (es) 2015-05-25
JP5753783B2 (ja) 2015-07-22
HRP20150223T8 (hr) 2015-07-03
SI3120869T1 (sl) 2020-10-30
HUE031030T2 (en) 2017-06-28
HRP20160915T1 (hr) 2016-10-07
LT3124043T (lt) 2020-07-10
DK2341927T3 (en) 2016-08-15
CA2936920A1 (en) 2010-04-08
US10046037B2 (en) 2018-08-14
HRP20150223T1 (hr) 2015-06-05
SI3069728T1 (sl) 2019-03-29
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
HUE049367T2 (hu) 2020-09-28
HUE050428T2 (hu) 2020-12-28
RS55543B1 (sr) 2017-05-31
AU2009300087A1 (en) 2010-04-08
EA032437B1 (ru) 2019-05-31
US20150125478A1 (en) 2015-05-07
CY1119744T1 (el) 2018-06-27
JP2016047825A (ja) 2016-04-07
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
EP2172212A2 (en) 2010-04-07
ES2804723T3 (es) 2021-02-09
WO2010037513A1 (en) 2010-04-08
PL3124043T3 (pl) 2020-07-27
JP5883476B2 (ja) 2016-03-15
CA2936869C (en) 2019-08-06
RS55531B1 (sr) 2017-05-31
US20120141517A1 (en) 2012-06-07
SI3120870T1 (sl) 2020-08-31
LT2172212T (lt) 2016-11-10
DK2172211T3 (en) 2015-02-16
PT3111952T (pt) 2019-02-05
SI3111952T1 (sl) 2019-01-31
EP3132801B1 (en) 2019-10-30
CN102170901A (zh) 2011-08-31
CA2936982A1 (en) 2010-04-08
CA2936924A1 (en) 2010-04-08
US10227381B2 (en) 2019-03-12
RS60386B1 (sr) 2020-07-31
TR201900852T4 (tr) 2019-02-21
KR101883426B1 (ko) 2018-07-31
US10047123B2 (en) 2018-08-14
EP3106175B1 (en) 2020-04-01
EP3111952A1 (en) 2017-01-04
US10919931B2 (en) 2021-02-16
US20160376315A1 (en) 2016-12-29
DK2172212T3 (da) 2016-12-19
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
RS60381B1 (sr) 2020-07-31
JP5855940B2 (ja) 2016-02-09
PT3120869T (pt) 2020-09-22
BRPI0920791B8 (pt) 2022-02-15
US20160376314A1 (en) 2016-12-29
US10941181B2 (en) 2021-03-09
EP3124043A1 (en) 2017-02-01
ES2708654T3 (es) 2019-04-10
DK3069728T3 (en) 2019-02-25
US11136352B2 (en) 2021-10-05
ES2607460T3 (es) 2017-03-31
LT3106175T (lt) 2020-08-10
PL3132801T3 (pl) 2020-06-15
HUE051030T2 (hu) 2021-01-28
DK3106175T3 (da) 2020-06-22
ES2819244T3 (es) 2021-04-15
CN106986919A (zh) 2017-07-28
BRPI0920759A2 (pt) 2016-03-08
AU2009300088A1 (en) 2010-04-08
BRPI0920791B1 (pt) 2022-01-18
SI3132801T1 (sl) 2020-03-31
EA201100586A1 (ru) 2011-10-31
EP2341927A2 (en) 2011-07-13
US20210238227A1 (en) 2021-08-05
DK3120869T3 (da) 2020-08-10
HUE029360T2 (en) 2017-02-28
PL3111952T3 (pl) 2019-04-30
HUE047365T2 (hu) 2020-04-28
HUE049364T2 (hu) 2020-09-28
PT3124043T (pt) 2020-05-12
CA2739384A1 (en) 2010-04-08
JP2017018102A (ja) 2017-01-26
PT3106175T (pt) 2020-07-01
CN102170900B (zh) 2016-10-26
HK1161106A1 (en) 2012-08-24
EP3120868B1 (en) 2020-04-08
PL3106175T3 (pl) 2020-08-24
ES2612466T3 (es) 2017-05-17
KR20110074894A (ko) 2011-07-04
LT2331118T (lt) 2016-12-27
US20130004456A1 (en) 2013-01-03
UA103202C2 (ru) 2013-09-25
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
PL2172211T3 (pl) 2015-05-29
US20210347822A1 (en) 2021-11-11
US11208434B2 (en) 2021-12-28
HRP20200110T1 (hr) 2020-05-15
HRP20201015T8 (hr) 2022-01-21
ES2584245T3 (es) 2016-09-26
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
EP3120869A1 (en) 2017-01-25
US10906936B2 (en) 2021-02-02
CY1116302T1 (el) 2017-02-08
HRP20201025T1 (hr) 2020-12-25
EP2331118B1 (en) 2016-10-26
PL2331118T3 (pl) 2017-05-31
US9993540B2 (en) 2018-06-12
TR201900809T4 (tr) 2019-02-21
CA2739387A1 (en) 2010-04-08
EP2172211B1 (en) 2014-12-03
DK3120870T3 (da) 2020-06-22
SI2172212T1 (sl) 2016-12-30
PT3069728T (pt) 2019-02-13
HRP20201228T1 (hr) 2021-02-05
RS55043B1 (sr) 2016-12-30
JP6297632B2 (ja) 2018-03-20
US8119139B2 (en) 2012-02-21
CA2936868C (en) 2019-10-22
LT3120868T (lt) 2020-08-10
EP3132801A1 (en) 2017-02-22
KR102392070B1 (ko) 2022-04-29
NZ624533A (en) 2015-09-25

Similar Documents

Publication Publication Date Title
HRP20161504T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
HRP20150852T1 (hr) Nova imunoterapija protiv tumora mozga
HRP20191009T1 (hr) Personalizirana imunoterapija protiv nekoliko neuronalnih i moždanih tumora
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20150300T4 (hr) Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2017502076A5 (hr)
JP2012504393A5 (hr)
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2010534463A5 (hr)
MY189042A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MX2018011223A (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer.
PH12018501933A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
JP2010534464A5 (hr)
JP2011520436A5 (hr)
US11377501B2 (en) Peptide having high affinity for PD-L1 protein and use thereof
PH12018501892A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20151313T1 (hr) Nova imunoterapija protiv neuronskih tumora i tumora mozga
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
Levy et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response